PDS Biotechnology Corporation (NASDAQ:PDSB) has announced that it has received a patent for its proprietary Versamune® T-cell activating technology by the USPTO. The company received Patent No. 10,828,364 titled “Method for Reducing a Myeloid Derived Suppressor Cell Population With Cationic Lipid Vaccine Composition.”
A patent to protect Versamune® tech
Dr. Frank Bedu-Addo, the company’s CEO, said that the patent award is a massive development as it will offer broad protection to the company’s proprietary Versamune® tech platform. He said that currently, there are three active mid-stage clinical PSA0101 studies, its lead program, partnered with leading companies in immune-oncology. Frank stated that they are optimistic that the Versamune® platform will offer enhanced clinical outcomes for patients.
The patent offers protection for the Versamune® platform, which includes chemical design as well as the method of use. Most importantly, the patent covers reduction methods for myeloid-derived suppressor cell populations known for immune response suppression. The reduction methods achieve suppression by administering positively charged cationic lipid in combination with therapeutic factors that include interleukins and cytokines.
Equally, the patent will cover the cationic lipid combination with therapeutic factor to supplement anti-tumor immune response. The company has a broader patent portfolio covering broader cationic lipid compositions as well as immune system activating methods. Versamune® combination with different antigens established the basis for PDS Biotech’s broad immune-oncology pipeline that includes PDS0101, the company’s lead product candidate for treating advanced human papillomavirus-related cancers.
PDS Biotech’s work supported by the US government
the company conducted part of the work leading to the innovative product with US government support under the National Cancer Institute CRADA No. 2644. As a result, the US government will have some rights in and to the current invention. The Versamune technology helps in the delivery of disease-specific antigens for processing and in Vivo uptake. At the same time, it also activates the critical type 1 interferon immunological pathway, which results in the production of strong disease-specific T Cells and neutralizing antibodies. So far, the company has engineered several therapies based on Versamune® combinations and disease-specific antigens.
